Clinical relevance of IL-6 gene rs1800795 polymorphism in patients with ischemic heart disease and chronic heart failure

Abstract

BACKGROUND: Inflammatory cascade contributes to the development of chronic heart failure. In this way, Interleukin-6 measurement in serum is relevant for understanding a course and prognosis in patients with chronic heart failure. Interleukin-6 expression correlates with IL-6 gene rs1800795 polymorphism.

AIM: This study analyzes the research articles about Interleukin-6 effects and IL-6 gene rs1800795 polymorphism in the patients with cardiovascular diseases with ischemic etiology.

MATERIALS AND METHODS: Systematic review and synthesis of findings of independent studies addressing the association between Interleukin-6 measurement and IL-6 gene rs1800795 polymorphism in the patients with coronary artery disease and chronic heart failure, including prognosis assessment.

RESULTS: The articles that were focused on the clinical features and outcomes in the patients with coronary artery disease and chronic heart failure depending on Interleukin-6 level have been analyzed. IL-6 gene rs1800795 polymorphism and its clinical significance have been introduced from the perspective of Interleukin-6 expression, C-reactive protein and lipids level in the blood. The meta-analysis data indicate the correlation between the rs1800795 and risk of coronary artery disease in comparison with homozygotes, as well as additive, recessive and dominant models. This review demonstrates relationship of polymorphism determination to left ventricular functioning, risks of chronic heart failure progression and future cardiovascular diseases.

CONCLUSIONS: The present study demonstrates that IL-6 gene rs1800795 polymorphism can provide comprehensive insights for prognosis assessment in patients with chronic heart failure.

Keywords

Interleukin 6 / IL-6 gene / rs1800795 polymorphism / coronary artery disease / chronic heart failure

References

[1] Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001;115(1):3–12. DOI: 10.1046/j.1365-2141.2001.03061

[2] Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis // Br. J. Haematol. 2001. Vol. 115. P. 3–12. DOI: 10.1046/j.1365-2141.2001.03061

[3] Su D, Li Z, Li X, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm. 2013;2013:726178. DOI: 10.1155/2013/726178

[4] Su D., Li Z., Li X. et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease // Mediators Inflamm. 2013. Vol. 2013. P. 726178. DOI: 10.1155/2013/726178

[5] Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156. DOI: 10.1161/CIRCRESAHA.115.306656

[6] Ridker P.M. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving upstream to identify novel targets for atheroprotection // Circ. Res. 2016. Vol. 118, No. 8. P. 145–156. DOI: 10.1161/CIRCRESAHA.115.306656

[7] Klimushina MV, Gumanova NG, Kutsenko VA, et al. Association of common polymorphisms in IL-6 and IL6ST genes with levels of inflammatory markers and coronary stenosis. Meta Gene. 2019;21:100593. DOI: 10.1016/j.mgene.2019.100593

[8] Klimushina M.V., Gumanova N.G., Kutsenko V.A. et al. Association of common polymorphisms in IL-6 and IL6ST genes with levels of inflammatory markers and coronary stenosis // Meta Gene. 2019. Vol. 21. P. 100593. DOI: 10.1016/j.mgene.2019.100593

[9] Haugen E, Gan LM, Isic A, et al. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol. 2008;13(1):19–24.

[10] Haugen E., Gan L.M., Isic A. et al. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients // Exp. Clin. Cardiol. 2008. Vol. 13, No. 1. P. 19–24.

[11] Eskandari V, Amirzargar AA, Mahmoudi MJ, et al. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure. Ir J Med Sci. 2018;187(2):359–368. DOI: 10.1007/s11845-017-1680-2

[12] Eskandari V., Amirzargar A.A., Mahmoudi M.J. et al. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure // Ir. J. Med. Sci. 2018. Vol. 187, No. 2. P. 359–368. DOI: 10.1007/s11845-017-1680-2

[13] Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965–973. DOI: 10.1002/ejhf.1482

[14] Markousis-Mavrogenis G., Tromp J., Ouwerkerk W. et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study // Eur. J. Heart Fail. 2019. Vol. 21, No. 8. P. 965–973. DOI: 10.1002/ejhf.1482

[15] Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275(24):18138–18144. DOI: 10.1074/jbc.M000379200

[16] Terry C.F., Loukaci V., Green F.R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation // J. Biol. Chem. 2000. Vol. 275, No. 24. P. 18138–18144. DOI: 10.1074/jbc.M000379200

[17] Niu W, Liu Y, Qi Y, et al Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243–252. DOI: 10.1016/j.ijcard.2011.12.098

[18] Niu W., Liu Y., Qi Y. et al. Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach // Int. J. Cardiol. 2012. Vol. 157, No. 2. P. 243–252. DOI: 10.1016/j.ijcard.2011.12.098

[19] Hou H, Wang C, Sun F, et al. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis. Inflamm Res. 2015;64(9):707–720. DOI: 10.1007/s00011-015-0850-9

[20] Hou H., Wang C., Sun F. et al. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis // Inflamm. Res. 2015. Vol. 64, No. 9. P. 707–720. DOI: 10.1007/s00011-015-0850-9

[21] Liu SL, Yin YW, Sun QQ, et al. Genetic polymorphisms of interleukin-6 gene and susceptibility to coronary artery disease in Chinese population: Evidence based on 4582 subjects. Hum Immunol. 2015;76(7):505–510. DOI: 10.1016/j.humimm.2015.06.004

[22] Liu S.L., Yin Y.W., Sun Q.Q. et al. Genetic polymorphisms of interleukin-6 gene and susceptibility to coronary artery disease in Chinese population: Evidence based on 4582 subjects // Hum. Immunol. 2015. Vol. 76, No. 7. P. 505–510. DOI: 10.1016/j.humimm.2015.06.004

[23] Zheng GH, Chen HY, Xiong SQ. Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies. PLoS One. 2012;7(4):e34839. DOI: 10.1371/journal.pone.0034839

[24] Zheng G.H., Chen H.Y., Xiong S.Q. Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies // PLoS One. 2012. Vol. 7, No. 4. P. e34839. DOI: 10.1371/journal.pone.0034839

[25] 1000Genome [Internet]. Available from: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:22726526-22727526;v=rs1800795;vdb=variation;vf=729516845#373520_table. Accessed: June 21, 2022.

[26] 1000Genome [Электронный ресурс]. Режим доступа: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core; r=7:22726526-22727526;v=rs1800795;vdb=variation;vf=729516845# 373520_table. Дата обращения: 22.06.2022.

[27] Genotype-Tissue Expression. [Internet]. Available from: https://gtexportal.org/home/snp/rs1800795. Accessed: June 21, 2022.

[28] Genotype-Tissue Expression [Электронный ресурс]. Режим доступа: https://gtexportal.org/home/snp/rs1800795. Дата обращения: 21.06.2022.

[29] Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2001;24(11):701–704. DOI: 10.1002/clc.4960241103

[30] Ikeda U., Ito T., Shimada K. Interleukin-6 and acute coronary syndrome // Clin Cardiol. 2001. Vol. 24, No. 11. P. 701–704. DOI: 10.1002/clc.4960241103

[31] Sie MP, Sayed-Tabatabaei FA, Oei HH, et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol. 2006;26(1):212–217. DOI: 10.1161/01.ATV.0000194099.65024.17

[32] Sie M.P., Sayed-Tabatabaei F.A., Oei H.H. et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis // Arterioscler. Thromb. Vasc. Biol. 2006. Vol. 26, No. 1. P. 212–217. DOI: 10.1161/01.ATV.0000194099.65024.17

[33] Khidirova LD, Yakhtonov DA, Maximov VN, Zenin SA. The association of genotype and alleles 174G/C (rs1800795) frequency of IL6 gene with clinical data in patients with atrial fibrillation, arterial hypertension in combination with extra-cardiac pathology. International Heart and Vascular Disease Journal. 2019;7(21):12–19. (In Russ.). DOI: 10.24412/2311-1623-2019-21-12-19

[34] Хидирова Л.Д., Яхонтов Д.А., Максимов В.Н., Зенин С.А. Ассоциация частоты генотипа и аллелей-174G/C (rs1800795) гена IL6 с клиническими данными у пациентов с фибрилляцией предсердий при гипертонической болезни в сочетании с экстракардиальной патологией // Международный журнал сердца и сосудистых заболеваний. 2019. Т. 7, № 21. С. 12–19. DOI: 10.24412/2311-1623-2019-21-12-19

[35] Shamonina TN, Radaeva OA, Novikova LV, Trofimov VA. Polymorphism of IL-6 genes in arterial hypertension in patients with metabolic syndrome. Fundamental Research. 2014;10(8):1591–1594. (In Russ.)

[36] Шамонина Т.Н., Радаева О.А., Новикова Л.В., Трофимов В.А. Полиморфизм генов IL-6 при артериальной гипертензии у пациентов с метаболическим синдромом // Фундаментальные исследования. 2014. Т. 10, № 8. С. 1591–1594.

[37] Shevchenko AV, Golovanova OV, Konenkov VI, et al. Analysis of correlation between il6 gene polymorphism (-174 g /c) and classic risk factors in patients with previous myocardial infarctions. Medical Immunology (Russia). 2009;11(6):557–566. (In Russ.). DOI: 10.15789/1563-0625-2009-6-557-566

[38] Шевченко А.В., Голованова О.В., Коненков В.И. и др. Анализ взаимосвязи полиморфизма гена il6 (-174 g/c) и классических факторов риска у пациентов с острым инфарктом миокарда в анамнезе // Медицинская иммунология. 2009. Т. 11, № 6. С. 557–566. DOI: 10.15789/1563-0625-2009-6-557-566

[39] Di Bona D, Vasto S, Capurso C, et al. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev. 2009;8(1):36–42. DOI: 10.1016/j.arr.2008.09.001

[40] Di Bona D., Vasto S., Capurso C. et al. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis // Ageing Res. Rev. 2009. Vol. 8, No. 1. P. 36–42. DOI: 10.1016/j.arr.2008.09.001

[41] Yin YW, Li JC, Zhang M, et al. Influence of interleukin-6 gene -174G>C polymorphism on development of atherosclerosis: a meta-analysis of 50 studies involving 33,514 subjects. Gene. 2013;529(1):94–103. DOI: 10.1016/j.gene.2013.07.074

[42] Yin Y.W., Li J.C., Zhang M. et al. Influence of interleukin-6 gene -174G>C polymorphism on development of atherosclerosis: a meta-analysis of 50 studies involving 33,514 subjects // Gene. 2013. Vol. 529, No. 1. P. 94–103. DOI: 10.1016/j.gene.2013.07.074

[43] Smith AJ, D’Aiuto F, Palmen J, et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem. 2008;54(5):841–850. DOI: 10.1373/clinchem.2007.098608

[44] Smith A.J., D’Aiuto F., Palmen J. et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism // Clin. Chem. 2008. Vol. 54, No. 5. P. 841–850. DOI: 10.1373/clinchem.2007.098608

[45] Salari N, Mansouri K, Hosseinian-Far A, et al. The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis. Genes Environ. 2021;43(1):1. DOI: 10.1186/s41021-021-00172-8

[46] Salari N., Mansouri K., Hosseinian-Far A. et al. The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis // Genes Environ. 2021. Vol. 43. P. 1. DOI: 10.1186/s41021-021-00172-8

[47] Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243–2252. DOI: 10.1053/euhj.2001.2678

[48] Humphries S.E., Luong L.A., Ogg M.S. et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men // Eur. Heart J. 2001. Vol. 22. P. 2243–2252. DOI: 10.1053/euhj.2001.2678

[49] Li L, Li E, Zhang LH, et al. IL-6-174G/C and IL-6-572C/G polymorphisms are associated with increased risk of coronary artery disease. Genet Mol Res. 2015;14(3):8451–8457. DOI: 10.4238/2015.July.28.12

[50] Li L., Li E., Zhang L.H. et al. IL-6-174G/C and IL-6-572C/G polymorphisms are associated with increased risk of coronary artery disease // Genet Mol. Res. 2015. Vol. 14, No. 3. P. 8451–8457. DOI: 10.4238/2015.July.28.12

[51] Rai H, Colleran R, Cassese S, et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. Inflamm Res. 2021;70(10–12):1075–1087. DOI: 10.1007/s00011-021-01505-7

[52] Rai H., Colleran R., Cassese S. et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis // Inflamm. Res. 2021. Vol. 70. P. 1075–1087. DOI: 10.1007/s00011-021-01505-7

[53] González-Castro TB, Hernández-Díaz Y, Pérez-Hernández N, et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases: a meta-analysis of 74 studies with 86,229 subjects. EXCLI J. 2019;18:331–355. DOI: 10.17179/excli2019-1248

[54] González-Castro T.B., Hernández-Díaz Y., Pérez-Hernández N. et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases: a meta-analysis of 74 studies with 86,229 subjects // EXCLI J. 2019. Vol. 18. P. 331–355. DOI: 10.17179/excli2019-1248

[55] Tabaei S, Motallebnezhad M, Tabaee SS. Systematic review and meta-analysis of association of polymorphisms in inflammatory cytokine genes with coronary artery disease. Inflamm Res. 2020;69(10):1001–1013. DOI: 10.1007/s00011-020-01385-3

[56] Tabaei S., Motallebnezhad M., Tabaee S.S. Systematic review and meta-analysis of association of polymorphisms in inflammatory cytokine genes with coronary artery disease // Inflamm. Res. 2020. Vol. 69, No. 10. P. 1001–1013. DOI: 10.1007/s00011-020-01385-3

[57] Kim SK, Chung JH, Kwon OY. Promoter polymorphism (-174, G/C) of Interleukin-6 and arterial thromboembolic events: a meta-analysis. Med Sci Monit. 2016;22:4345–4353. DOI: 10.12659/MSM.901467

[58] Kim S.K., Chung J.H., Kwon O.Y. Promoter Polymorphism (-174, G/C) of Interleukin-6 and Arterial Thromboembolic Events: A Meta-Analysis // Med. Sci. Monit. 2016. Vol. 14, No. 22. P. 4345–4353. DOI: 10.12659/MSM.901467

[59] Minushkina LO, Chumakova OS, Selezneva ND, et al. Left ventricular hypertrophy development, associated with genetic polymorphism of inflammatory mediators. Russian Journal of Cardiology. 2014;10:23–28. (In Russ.). DOI: 10.15829/1560-4071-2014-10-23-28

[60] Minushkina L.O., Chumakova O.S., Selezneva N.D. et al. Left ventricular hypertrophy development, associated with genetic polymorphism of inflammatory mediators // Russian Journal of Cardiology. 2014. Vol.10. P. 23–28. DOI: 10.15829/1560-4071-2014-10-23-28

[61] Bielecka-Dabrowa A, Sakowicz A, Misztal M, et al. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. Int J Cardiol. 2016;221:1073–1080. DOI: 10.1016/j.ijcard.2016.07.150

[62] Bielecka-Dabrowa A., Sakowicz A., Misztal M. et al. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies // Int. J. Cardiol. Vol. 15, No. 221. P. 1073–1080. DOI: 10.1016/j.ijcard.2016.07.150

[63] Hedayat M, Mahmoudi MJ, Taghvaei M, et al. Tumor Necrosis Factor-Alpha and Interleukin-6 Gene Polymorphisms in Iranian Patients with Ischemic Heart Failure. Avicenna J Med Biotechnol. 2018;10(2):105–109.

[64] Hedayat M., Mahmoudi M.J., Taghvaei M. et al. Tumor necrosis factor-alpha and interleukin-6 gene polymorphisms in iranian patients with ischemic heart failure // Avicenna J. Med. Biotechnol. 2018. Vol. 10, No. 2. P. 105–109.

[65] Kravchun PG, Kadykova OI, Ryndina NG, et al. Relationship between interleukin-6 gene polymorphism and heart failure in patients with coronary artery disease and obesity. Wiad Lek. 2020;73(8):1637–1640.

[66] Kravchun P.G., Kadykova O.I., Ryndina N.G. et al. Relationship between interleukin-6 gene polymorphism and heart failure in patients with coronary artery disease and obesity // Wiad. Lek. 2020. Vol. 73, No. 8. P. 1637–1640.

[67] Mishra A, Srivastava A, Mittal T, et al. Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients. Cytokine. 2013;61(3):856–861. DOI: 10.1016/j.cyto.2012.12.020

[68] Mishra A., Srivastava A., Mittal T. et al. Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients // Cytokine. 2013. Vol. 61, No. 3. P. 856–861. DOI: 10.1016/j.cyto.2012.12.020

[69] Bielecka-Dabrowa A, Sakowicz A, Pietrucha T, et al. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. Sci Rep. 2017;7(1):8974. DOI: 10.1038/s41598-017-09564-9

[70] Bielecka-Dabrowa A., Sakowicz A., Pietrucha T. et al. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction // Sci. Rep. 2017. Vol. 7. P. 8974. DOI: 10.1038/s41598-017-09564-9

RIGHTS & PERMISSIONS

Khazova E.V., Valiakhmetov R.V., Murzakova A.R., Bulashova O.V.